

Electronic Acknowledgement Receipt

EFS ID:	3120289
Application Number:	10828398
International Application Number:	
Confirmation Number:	4829
Title of Invention:	Pharmaceutical compositions of atorvastatin
First Named Inventor/Applicant Name:	Paul E. Luner
Customer Number:	28880
Filer:	J. Michael Dixon/Kelly Smith
Filer Authorized By:	J. Michael Dixon
Attorney Docket Number:	PC25686A
Receipt Date:	08-APR-2008
Filing Date:	20-APR-2004
Time Stamp:	15:27:00
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 720
RAM confirmation Number	585
Deposit Account	161445
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Extension of Time	PC25686A-Pet_Ext_Time.pdf	33079 b05da2548f5e9e5015c030176b615166132e8	no	1
Warnings:					
Information:					
2		PC25686A-Amendment.pdf	306022 9d51f9377ba59969e619c0350d2d4dd25fcd77f6	yes	9
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment - After Non-Final Rejection		1	1	
	Claims		2	4	
	Applicant Arguments/Remarks Made in an Amendment		5	9	
Warnings:					
Information:					
3	Terminal Disclaimer Filed	PC25686A-Terminal_Disclaimer_10828079.pdf	68871 d07d10501d4ee451809b0720927dc4e45b59143	no	1
Warnings:					
Information:					
4	Terminal Disclaimer Filed	PC25686A-Terminal_Disclaimer_10828419.pdf	63965 3e41010b7579506a7982799e04a150caf56c993c	no	1
Warnings:					
Information:					
5	Fee Worksheet (PTO-06)	fee-info.pdf	8304 04c05263ba7d15e809e3336cd195acdf182ab7d1d	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			480241		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.